

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 1 of 4

ATTORNEY DOCKET NO.

SERIAL NO.

9692-000042/US

10/792,374

APPLICANT

Levy, et al.

FILING DATE

GROUP

March 3, 2004

Unknown

**U.S. PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date

**FOREIGN PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**

Ref. Desig.	Examiner's Initials	
1.	LY	Adida et al., <i>Prognostic significance of surviving expression in diffuse large B-cell lymphomas</i> , Blood, Vol. 96, No. 5, pp 1921-1925, 2000
2.		Alizadeh et al., <i>Distinct Types of Diffuse Large B-cell Lymphoma Identified by Gene Expression Profiling</i> , Nature, Vol. 403, pp 503-511, 2000
3.		Barrans et al., <i>Germinal center phenotype and bcl1-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma</i> , Blood, Vol. 99, No. 4, pp 1136-1143, 2002
4.		Boehm et al., <i>The rhombotin family of cysteine-rich LIM-domain oncogenes: Distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13</i> , Proc. Natl. Acad. Sci. U S A, Vol. 88, No. 10, pp 4367-4371, 1991
5.		Cattoretti et al., <i>BCL-6 Protein Is Expressed in Germinal-Center B Cells</i> , Blood, Vol. 86, No. 1, pp 45-53, 1995
6.		Chang et al., <i>BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor</i> , Proc. Natl. Acad. Sci. U S A, Vol. 93, pp 6947-6952, 1996
7.		Dent et al., <i>T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6</i> , Proc. Natl. Acad. Sci. U S A, Vol. 95, pp 13823-13828, 1998
8.		Freeman et al., <i>Quantitative RT-PCR: Pitfalls and Potential</i> , BioTechniques, Vol. 26, No. 1, pp 112-125, 1999

Examiner:

/Lei Yao/

Date Considered:

09/13/2006

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p><b>PATENT AND TRADEMARK OFFICE</b></p> <p><b>INFORMATION DISCLOSURE CITATION</b></p> <p>(Use several sheets if necessary)</p> <p>Sheet 2 of 4</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	9692-000042/US	10/792,374
	APPLICANT	
	Levy, et al.	
	FILING DATE	GROUP
	March 3, 2004	Unknown

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
9.	LY	Gascoyne et al., <i>Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma</i> , Blood, Vol. 90, No. 1, pp 244-251, 1997
10.		Harris et al., <i>A Revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group</i> , Blood, Vol. 84, No. 5, pp 1361-1392, 1994
11.		Hermine et al., <i>Prognostic Significance of bcl-2 Protein Expression in Aggressive Non-Hodgkin's Lymphoma</i> , Blood, Vol. 87, No. 1, pp 265-272, 1996
12.		Hill et al., <i>Prognostic Significance of BCL-2 Expression and bcl-2 Major Breakpoint Region Rearrangement in Diffuse Large Cell Non-Hodgkin's Lymphoma: A British National Lymphoma Investigation Study</i> , Blood, Vol. 88, No. 3, pp 1046-1051, 1996
13.		Ichikawa et al., <i>Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma</i> , New England J Med, Vol. 337, No. 8, pp 529-534, 1997
14.		Kaiser, <i>Seeking the Cause of Induced Leukemias in X-SCID Trial</i> , Science, Vol. 299, p 495, 2003
15.		Kerckaert et al., <i>LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas</i> , Nat. Genet, Vol. 5, pp 66-70, 1993
16.		Koduru et al., <i>Correlation Between Mutation in P53, p53 Expression, Cytogenetics, Histologic Type, and Survival in Patients With B-Cell Non-Hodgkin's Lymphoma</i> , Blood, Vol. 90, No. 10, pp 4078-4091, 1997
17.		Kramer et al., <i>Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma</i> , Blood, Vol. 92, No. 9, pp 3152-3162, 1998
18.		Kramer et al., <i>Clinical Significance of bcl2 and p53 Protein Expression in Diffuse Large B-Cell Lymphoma: A Population-Based Study</i> , J. Clin Onco, Vol. 14, No. 7, pp 2131-2138, 1996
19.		Krenacs et al., <i>Transcription Factor B-Cell-Specific Activator Protein (BSAP) Is Differentially Expressed in B Cells and in Subsets of B-Cell Lymphomas</i> , Blood, Vol. 92, No. 4, pp 1308-1316, 1998
20.		Livak et al., <i>Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2<sup>-ΔΔCT</sup> Method</i> , Methods, Vol. 25, pp 402-408, 2001
21.	✓	Lossos et al., <i>HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma</i> , Blood, Vol. 101, No. 2, pp 433-440, 2003

Examiner:	/Lei Yao/	Date Considered:	09/13/2006
-----------	-----------	------------------	------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p><b>PATENT AND TRADEMARK OFFICE</b></p> <p><b>INFORMATION DISCLOSURE CITATION</b></p> <p>(Use several sheets if necessary)</p> <p>Sheet 3 of 4</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	9692-000042/US	10/792,374
	APPLICANT	
	Levy, et al.	
	FILING DATE	GROUP
	March 3, 2004	Unknown

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
22.	LY	Lossos et al., <i>Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma</i> , Blood, Vol. 98, No. 4, pp 945-951, 2001
23.		Lossos et al., <i>Diffuse Large B-Cell Lymphoma: Insights Gained from Gene Expression Profiling</i> , Int. J. Hematol., Vol. 77, pp 321-329, 2003
24.		Lossos et al., <i>Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies</i> , Leukemia, Vol. 17, pp 789-795, 2003
25.		Miller et al., <i>Prognostic Significance of the Ki-67-Associated Proliferative Antigen in Aggressive Non-Hodgkin's Lymphomas: A Prospective Southwest Oncology Group Trial</i> , Blood, Vol. 83, No. 6, pp 1460-1466, 1994
26.		Pfaffl et al., <i>Relative expression software tool (REST®) for group-wise comparison and statistical analysis of relative expression results in real-time PCR</i> , Nucleic Acid Research, Vol. 30, No. 9, e36, pp 1-10, 2002
27.		Royer-Pokora et al., <i>TTG-2, a new gene encoding a cystein-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14) (p13;q11) Oncogene</i> , Vol. 6, pp 1887-1893, 1893
28.		Proost et al., <i>The Role of Chemokines in Inflammation</i> , Int. J. Clin. Lab. Res., Vol. 26, pp 211-223, 1996
29.		Rosenwald et al., <i>The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-Cell lymphoma</i> , N. Engl. J. Med., Vol. 346, No. 25, pp 1937-1947, 2002
30.		Seyfert et al., <i>Transcriptional repression by the proto-oncogene BCL-6</i> , Oncogene, Vol. 12, pp 2331-2342, 1996
31.		Shaffer et al., <i>BCL-6 Represses Genes that Function in Lymphocyte Differentiation, Inflammation, and Cell Cycle Control</i> , Immunity, Vol. 13, pp 199-212, 2000
32.		Shipp et al., <i>Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning</i> , Nat. Med., Vol. 8, No. 1, pp 68-74, 2002
33.		Terol et al., <i>Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome</i> , Ann Oncol, Vol. 14, pp 467-474, 2003
34.	↓	Shipp et al., <i>A Predictive Model For Aggressive Non-Hodgkin's Lymphoma</i> , The International Non-Hodgkin's Lymphoma Prognostic Factors Project, New England Journal Med., Vol. 329, No. 14, pp 987-994, 1993

Examiner:	/Lei Yao/	Date Considered:	09/13/2006
-----------	-----------	------------------	------------


EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p><b>PATENT AND TRADEMARK OFFICE</b></p> <p><b>INFORMATION DISCLOSURE CITATION</b></p> <p>(Use several sheets if necessary)</p> <p>Sheet 4 of 4</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	9692-000042/US	10/792,374
	APPLICANT	
	Levy, et al.	
	FILING DATE	GROUP
March 3, 2004	Unknown	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
35.	LY	The Non-Hodgkin's Lymphoma classification Project, <i>A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma</i> , Blood, Vol. 89, No. 11, pp 3909-3918, 1997
36.	↓	Tusher et al., <i>Significance analysis of microarrays applied to the ionizing radiation response</i> , Proc. Natl. Acad. Sci. U S A, Vol. 98, No. 9, pp 5116-5121, 2001
37.		Warren et al., <i>The Oncogenic Cysteine-Rich LIM Domain Protein Rbtl2 Is Essential for Erythroid Development</i> , Cell, Vol. 78, pp 45-57, 1994
38.		Yamada et al., <i>The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice</i> , Proc. Natl. Acad. Sci. U S A, Vol. 97, No. 1, pp 320-324, 2000
39.		Ye et al., <i>The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation</i> , Nat. Genet., Vol. 16, pp 161-170, 1997

Examiner:	/Lei Yao/	Date Considered:	09/13/2006
-----------	-----------	------------------	------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE**  
**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET NO.

9692-000013

SERIAL NO.

10/792,374

APPLICANT

Levy et al.

FILING DATE

March 3, 2004

GROUP

not yet assigned

**U.S. PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.						

**FOREIGN PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
1.							

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**

Ref. Desig.	Examiner's Initials	
1.	LY	Drillenburger, P. et al.; CD44 expression predicts disease outcome in localized large B cell lymphoma; Leukemia; pp. 1448-1455; (1999).


Examiner:

/Lei Yao/

Date Considered:

09/13/2006

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM HD-149 (Revised on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET NO.

9692-000042

SERIAL NO.

10/792,374

APPLICANT

Levy et al.

FILING DATE

March 3, 2004

GROUP

1642

**U.S. PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.						

**FOREIGN PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
1.							

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**

Ref. Desig.	Examiner's Initials	
1.	LY	Hans, C.P. et al.; "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray"; Blood; Vol. 103, No.1; September 22, 2003; pgs. 275-282.
2.	LY	Lossos, I.S. et al.; "Prediction of survival in diffuse large B-cell lymphoma based on the expression of six genes"; The New England Journal of Medicine; Vol. 350, No. 18; April 29, 2004; pgs. 1828-1837.
3.	LY	Wright, G. et al.; "A gene expression based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma"; Proceedings of the National Academy of Sciences of the United States of America; Vol. 100, No. 17, August 19, 2003

Examiner:

LY

/Lei Yao/

Date Considered:

09/13/2006

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>PATENT AND TRADEMARK OFFICE</b> <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  Sheet 1 of 3	HDP-1449 (Based on Form PTO-1449)	
	ATTORNEY DOCKET NO.	SERIAL No.
	9692-000042	10/792,374
	APPLICANT	
	Ronald Levy et al.	
	FILING DATE	GROUP
	March 3, 2004	1642

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.	LY	4,586,546	5/6/86	Mezei et al.		
2.		5,561,058	10/1/96	Gelfand et al.		
3.		5,618,703	4/8/97	Gelfand et al.		
4.		5,693,517	12/2/97	Gelfand et al.		
5.		5,876,978	3/2/99	Willey et al.		
6.		5,916,524	6/29/99	Tisone		
7.		5,998,768	12/7/99	Hunter et al.		
8.		5,999,209	12/7/99	Hunter et al.		
9.		6,005,664	12/21/99	Korenberg et al.		
10.		6,036,920	3/14/00	Pantoliano et al.		
11.		6,037,129	3/14/00	Cole et al.		
12.		6,087,098	7/11/00	McKiernan et al.		
13.		6,088,100	6/11/00	Brenan et al.		
14.		6,154,707	11/28/00	Livak et al.		
15.		6,203,759	3/20/01	Pelc et al.		
16.		6,214,293	4/10/01	Pantoliano et al.		
17.		6,235,520	5/22/01	Dehlinger et al.		
18.		6,300,073	10/9/01	Zhao et al.		
19.		6,309,608	10/30/01	Zhou et al.		
20.		6,358,679	3/19/02	Heid et al.		
21.		6,373,726	4/16/02	Russell		

Examiner: /Lei Yao/	Date Considered: 09/13/2006
---------------------	-----------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM HDP-1449 (Based on Form PTO-1449)</b>  <b>PATENT AND TRADEMARK OFFICE</b> <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  Sheet 2 of 3	ATTORNEY DOCKET NO.	SERIAL NO.
	9692-000042	10/792,374
	APPLICANT	
	Ronald Levy et al.	
	FILING DATE	GROUP
	March 3, 2004	1642

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
22.	LY	6,406,891	6/18/02	Legerski		
23.	↓	6,436,677	8/20/02	Gu et al.		
24.		6,448,089	9/10/02	Vuong		
25.		6,472,218	10/29/02	Stylli et al.		
26.		6,485,917	11/26/02	Yamamoto et al.		
27.		6,586,257	7/1/03	Vuong		
28.		6,638,483	10/28/03	Vuong		
29.		6,730,883	5/4/04	Brown et al.		
30.		6,814,933	11/9/04	Vuong		
31.		6,825,927	11/30/04	Goldman et al.		
32.		6,852,986	2/8/05	Lee et al.		
33.		2001/0049134	12/6/01	Lee et al.		
34.		2002/0090320	7/11/02	Burow et al.		
35.		2002/0098593	7/25/02	Nelson et al.		
36.		2002/0098598	7/25/02	Coffen et al.		
37.		2003/0027179	2/6/03	Heid et al.		
38.		2003/0087446	5/8/03	Eggers		
39.		2003/0108868	6/12/03	Richards		
40.		2003/0109060	6/12/03	Cook et al.		
41.		2003/0118483	6/26/03	Militzer et al.		

Examiner:	09/13/2006	Date Considered:	09/13/2006
-----------	------------	------------------	------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>FORM HDP-1449 (Based on Form PTO-1449)</b>  <b>PATENT AND TRADEMARK OFFICE</b> <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  Sheet 3 of 3	ATTORNEY DOCKET NO.	SERIAL No.
	9692-000042	10/792,374
	APPLICANT	
	Ronald Levy et al.	
	FILING DATE	GROUP
	March 3, 2004	1642

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
42.	LY	2003/0124539	7/3/03	Warrington et al.		
43.		2003/0136921	7/24/03	Reel		
44.		2003/0179639	8/7/03	Stolakis et al.		
45.		2003/0190652	10/9/03	De La Vega et al.		
46.		2003/0202637	10/30/03	Yang		
47.		2003/0205681	11/6/03	Modlin		
48.		2003/0207464	11/6/03	Lemmo et al.		
49.		2003/0215957	11/20/03	Lemmo et al.		
50.		2004/0014238	1/22/04	Krug et al.		
51.		2004/0018506	1/29/04	Koehler et al.		
52.		2004/0057870	3/25/04	Isaksson et al.		
53.		2004/0061071	4/1/04	Dorsel		
54.		2004/0131505	7/8/04	Koeda		
55.		2004/0202577	10/14/04	McNeil et al.		
56.		2004/0203047	10/14/04	Caren et al.		
57.	↓	2004/0203164	10/14/04	Cizdziel et al.		

FOREIGN PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No
1.		WO 2004/051218	6/17/04	WIPO		X

Examiner: /Lei Yao/	Date Considered: 09/13/2006
---------------------	-----------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.